Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

NCT01207440 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

449

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia
Ph+ Acute Lymphoblastic Leukemia

Interventions

DRUG: Ponatinib

Sponsor

Ariad Pharmaceuticals